Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma
- Authors:
- Bei-Ji Lu
- Yun-Qing Wang
- Xue-Jie Wei
- Liang-Qun Rong
- Dong Wei
- Chang-Ming Yan
- Deng-Jie Wang
- Jun-Ying Sun
View Affiliations
Affiliations: Department of Orthopedics, The First Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Orthopedics, the Second Affiliated Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China
- Published online on: January 30, 2012 https://doi.org/10.3892/mmr.2012.772
-
Pages:
1033-1036
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Osteosarcoma, a common malignancy primarily affecting children, generally has a poor prognosis. Novel diagnostic, prognostic and therapeutic markers are required to ameliorate the negative outcomes of this disease. We investigated two potential markers, WNT-5a and ROR2, which are hypothesized to dysregulate WNT signaling pathways to promote tumorigenesis in other types of cancer. We investigated WNT-5a and ROR2 expression using immunohistochemistry in 42 osteosarcoma and 12 osteochondroma specimens, and compared the expression of these proteins with one another as well as with clinicopathological parameters. WNT-5a was detected in 34/42 (81.0%) cases and ROR2 was detected in 31/42 (73.8%) cases, significantly higher than in osteochondroma (16.7 and 25.0%, respectively; both P<0.05). Expression of these proteins was positively correlated (r=0.552, P<0.05). Furthermore, expression of WNT-5a and ROR2 was both correlated with Enneking surgical stage and tumor metastasis (P<0.05), but not with patient gender, age or pathological type. Thus, WNT-5a and ROR2 were more highly expressed in more severe disease states, and therefore may play a coordinated role in the occurrence and progression of osteosarcoma.
View References
|
1
|
KK UnniOsteosarcoma of boneJ Orthop
Sci3287294199810.1007/s007760050055
|
|
2
|
VO LewisWhat’s new in musculoskeletal
oncologyJ Bone Joint Surg Am91154615562009
|
|
3
|
H WafaRJ GrimerSurgical options and
outcomes in bone sarcomaExpert Rev Anticancer
Ther6239248200610.1586/14737140.6.2.23916445376
|
|
4
|
PA MeyersCL SchwartzMD KrailoOsteosarcoma:
the addition of muramyl tripeptide to chemotherapy improves overall
survival – a report from the Children’s Oncology GroupJ Clin
Oncol266336382008
|
|
5
|
H YaoE AshiharaT MaekawaTargeting the
Wnt/β-catenin signaling pathway in human cancersExpert Opin Ther
Targets158738872011
|
|
6
|
J SylvieC EllenV KrisThe role of Wnt in
cell signaling and cell adhesion during early vertebrate
developmentFront Biosci1723522366201121622181
|
|
7
|
CC ClarkI CohenI EichstetterLA
CannizzaroJD McPhersonJJ WasmuthRV IozzoMolecular cloning of the
human proto-oncogene Wnt-5A and mapping of the gene (WNT5A) to
chromosome 3p14–p21Genomics182492601993
|
|
8
|
T PukropC BinderThe complex pathways of
Wnt 5a in cancer progressionJ Mol Med
(Berl)86259266200810.1007/s00109-007-0266-217952396
|
|
9
|
SL McDonaldA SilverThe opposing roles of
Wnt-5a in cancerBr J
Cancer101209214200910.1038/sj.bjc.660517419603030
|
|
10
|
J DejmekA DejmekA SäfholmA SjölanderT
AnderssonWnt-5a protein expression in primary Dukes B colon cancers
identifies a subgroup of patients with good prognosisCancer
Res6591429146200510.1158/0008-5472.CAN-05-171016230369
|
|
11
|
N KremenevskajaR von WasielewskiAS RaoC
SchöflT AnderssonG BrabantWnt-5a has tumor suppressor activity in
thyroid
carcinomaOncogene2421442154200510.1038/sj.onc.120837015735754
|
|
12
|
M KurayoshiN OueH YamamotoExpression of
Wnt-5a is correlated with aggressiveness of gastric cancer by
stimulating cell migration and invasionCancer
Res661043910448200610.1158/0008-5472.CAN-06-235917079465
|
|
13
|
E BlancD GoldschneiderS Douc-RasyJ BénardG
RaguénezWnt-5a gene expression in malignant human neuroblastsCancer
Lett228117123200510.1016/j.canlet.2004.11.06115925444
|
|
14
|
I OishiH SuzukiN OnishiThe receptor
tyrosine kinase Ror2 is involved in non-canonical Wnt-5a/JNK
signalling pathwayGenes
Cells8645654200310.1046/j.1365-2443.2003.00662.x12839624
|
|
15
|
K MoriokaC TanikawaK OchiOrphan receptor
tyrosine kinase ROR2 as a potential therapeutic target for
osteosarcomaCancer
Sci10012271233200910.1111/j.1349-7006.2009.01165.x19486338
|
|
16
|
WF EnnekingSS SpanierMA GoodmanA system
for the surgical staging of musculoskeletal sarcomaClin Orthop
Relat Res418200310.1097/01.blo.0000093891.12372.0f14612624
|
|
17
|
CL HuangD LiuJ NakanoWnt-5a expression is
associated with the tumor proliferation and the stromal vascular
endothelial growth factor – an expression in non-small-cell lung
cancerJ Clin Oncol2387658773200516314637
|
|
18
|
XH LiuMH PanZF LuExpression of Wnt-5a and
its clinicopathological significance in hepatocellular carcinomaDig
Liver Dis40560567200810.1016/j.dld.2007.12.01118294932
|
|
19
|
J SchlessingerCell signaling by receptor
tyrosine
kinaseCell103211225200010.1016/S0092-8674(00)00114-811057895
|
|
20
|
AR AfzralS JefferyOne gene, two
phenotypes: ROR2 mutations in autosomal recessive Robinow syndrome
and autosomal dominant brachydactyly type BHum
Mutat22111200310.1002/humu.1023312815588
|
|
21
|
AJ MikelsR NussePurified Wnt5a protein
activates or inhibits beta-catenin-TCF signaling depending on
receptor contextPLoS
Biol4e115200610.1371/journal.pbio.004011516602827
|
